Turning Point Gets FDA OK for Elzovantinib/Aumolertinib Combo Study
January 20 2022 - 9:52AM
Dow Jones News
By Colin Kellaher
Turning Point Therapeutics Inc. on Thursday said it received
U.S. Food and Drug Administration approval to study its
elzovantinib drug candidate in combination with EQRx Inc.'s
aumolertinib in EGFR mutant MET-amplified advanced non-small cell
lung cancer.
The San Diego clinical-stage oncology company said it expects to
initiate the Phase 1b/2 study in mid-2022.
Aumolertinib is approved in China for first-line treatment of
EGFR mutant non-small cell lung cancer and second-line treatment of
T790M+ EGFR mutant non-small cell lung cancer.
Turning Point said the study will evaluate the safety,
tolerability and preliminary efficacy of the combination
elzovantinib/aumolertinib regimen.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 20, 2022 09:37 ET (14:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
EQRx (NASDAQ:EQRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
EQRx (NASDAQ:EQRX)
Historical Stock Chart
From Sep 2023 to Sep 2024